Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status

Human Pathology

Volumn 35, Issue 7, 2004, Pages 817-824

  Le Frère Belda, Marie Aude ^b   Gil Diez De Medina, Sixtina ^b   Daher, Ahmad ^b   Martin, Nadine ^b   Albaud, Benoit ^b   Heudes, Didier ^b   Abbou, Clément Claude ^b   Thiery, Jean Paul ^b   Zafrani, Élie Serge ^b   Radvanyi, Francois ^b   Chopin, Dominique ^a  

^a FACULTÉ DE MÉDECINE   (France)

^b NONE

Author keywords

cdk; cyclin D dependent kinase; GAPDH; labeling index; LI; p14ARF; p16; p53; pRb; retinoblastoma protein; reverse transcription polymerase chain reaction; RT PCR; TATA binding protein; TBP; UCs; urothelial carcinomas

Indexed keywords

GENE PRODUCT; PROTEIN P14ARF; PROTEIN P16; PROTEIN P53;

ARTICLE; CORRELATION ANALYSIS; DELETION MUTANT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; URINARY TRACT CARCINOMA; UROTHELIUM;

CARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 3142606708     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2004.01.019     Document Type: Article

References (33)

1. Reznikoff C.A., Belair C.D., Yeager T.R., et al. A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol. 23:1996;571-584
2. Mao L., Merlo A., Bedi G., et al. A novel p16INK4A transcript. Cancer Res. 55:1995;2995-2997
3. Quelle D.E., Zindy F., Ashmun R.A., et al. Alternative reading frames of theINK4 tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83:1995;993-1000
4. Stone S., Jiang P., Dayananth P., et al. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res. 55:1995;2988-2994
5. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707
6. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677
7. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:1998;713-723
8. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53 ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:1998;725-734
9. ARF links the tumour suppressors RB and p53. Nature. 395:1998;124-125
10. Cordon-Cardo C., Zhang Z.F., Dalbagni G., et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res. 57:1997;1217-1221
11. International Union Against Cancer. TNM Classification of Malignant Tumours. 6th ed. 2002;Wiley-Liss, New York
12. World Health Organization. Histological Typing of Urinary Bladder Tumours. 1973;World Health Organization, Geneva, Switzerland
13. Gil Diez de Medina S., Chopin D., El Marjou A., et al. Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene. 14:1997;323-330
14. INK4b in bladder carcinomas Decreased expression in superficial tumours. Br J Cancer. 85:2001;1515-1521
15. Popov Z., Hoznek A., Colombel M., et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer. 80:1997;1472-1481
16. Resnick J.M., Cherwitz D., Knapp D., et al. A microwave method that enhances detection of aberrant p53 expression in formalin-fixed, paraffin-embedded tissues. Arch Pathol Lab Med. 119:1995;360-366
17. Sharpless N.E., DePinho R.A. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev. 9:1999;22-30
18. Sherr C.J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:1998;2984-2991
19. Yeager T., Stadler W., Belair C., et al. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res. 55:1995;493-497
20. Stadler W.M., Olopade O.I. The 9p21 region in bladder cancer cell lines Large homozygous deletions inactivate the CDKN2, CDKN2B and MTAP genes. Urol Res. 24:1996;239-244
21. Benedict W.F., Lerner S.P., Zhou J., et al. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene. 18:1999;1197-1203
22. Orlow I., LaRue H., Osman I., et al. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol. 155:1999;105-113
23. Friedrich M.G., Blind C., Milde-Langosch K., et al. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. Eur Urol. 40:2001;518-524
24. Wu W.J., Kakehi Y., Chang S.F., et al. Genetic alterations of the p16 gene in urothelial carcinoma in Taiwanese patients. BJU Int. 85:2000;143-149
25. INK4a expression. Mod Pathol. 14:2001;1162-1168
26. Markl I.D.C., Jones P.A. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res. 58:1998;5348-5353
27. INK4a gene is frequently lost in small cell lung cancer. Cancer Res. 58:1998;3926-3931
28. Sanchez-Cespedes M., Reed A.L., Buta M., et al. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene. 18:1999;5843-5849
29. Sarkar S., Jülicher K.P., Burger M.S., et al. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res. 60:2000;3862-3871
30. Stott F.J., Bates S., James M.C., et al. The alternative product from the CDKN2A locus, p14 (ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:1998;5001-5014
31. INK4a expression in resected non-small cell lung tumors. Cancer Res. 56:1996;3415-3420
32. INK4A in archival human solid tumors Correlation with retinoblastoma protein expression. Cancer Res. 55:1995;6006-6011
33. Cote R.J., Dunn M.D., Chatterjee S.J., et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 58:1998;1090-1094